Haemostyptic effects of batroxobin with regard to hirudin treatment.
In contrast to thrombin the fibrinogen coagulant effect of the thrombin-like enzyme batroxobin in vitro and in vivo is not inhibited by the specific thrombin inhibitor hirudin. The haemostyptic effect of batroxobin has been studied in rats after bleeding had been induced by corresponding hirudin dosages. Dependent on batroxobin concentration bleeding time was shortened by local application of batroxobin containing solutions. Strong bleeding induced by i.v. injection of 5 mg r-hirudin/kg was stopped almost immediately when a batroxobin concentration of 40 BU/ml was used. Thrombin was less active to stop bleeding after r-hirudin administration than batroxobin.
Markwardt
F
F
Institute of Pharmacology and Toxicology, Medical School Erfurt, FRG.
Kaiser
B
B
Richter
M
M
D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology*; D012103:Batroxobin / Q000494:pharmacology*; D001760:Bleeding Time; D004347:Drug Interactions; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000633:toxicity; D006470:Hemorrhage / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects*; D006629:Hirudins / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000633:toxicity; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000633:toxicity; D013917:Thrombin / Q000494:pharmacology
D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins; D012103:Batroxobin; D013917:Thrombin; C060225:desirudin